Six-Gene Signature Predicted Melanoma Relapse
Researchers identified a genetic profile that helps determine which patients are at higher risk for melanoma spread.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you believe new genetic research methods will significantly improve future cancer treatment outcomes?
A new six-gene signature called OncoCycle accurately predicted melanoma relapse independently of traditional clinical features in a study of 247 patients. The findings offer a potential new tool for identifying which early-stage skin cancers are most likely to progress.
Why it matters
Identifying metastatic potential early is critical because it could improve risk assessment and treatment monitoring for those with primary cutaneous melanoma. This research suggests that certain genetic markers prime cells for spread long before clinical progression is visible.
In a study following 247 primary cutaneous melanomas over a median of 92 months, researchers found that the six-gene OncoCycle signature predicted relapse independently of other clinical factors. These preliminary findings highlight the importance of specific copy-number alterations.
The players
Columbia University
An academic research institution that hosted the study investigating the genetic drivers of cancer progression.
The details
The OncoCycle signature tracks specific chromosomal changes, including the amplification of CDK4, MCL1, and CD276, paired with the loss of CDKN2A, CDKN2B, and TP53BP1. By integrating sequencing, protein analysis, and spatial transcriptomics, the team observed how these alterations drive metastatic evolution. These genetic changes allow cancer cells to adapt and survive within immune and stromal niches, effectively priming them for spread early in the tumor's development.
Timeline
92 months was the median follow-up period for the registry cohort.
Health Landscape
This work refines findings from the TCGA melanoma project by focusing on the specific metastatic potential of primary tumors. It advances the field by moving beyond general genomic profiling to identify actionable signatures that predict clinical outcomes.
If you have a history of cutaneous melanoma, these findings represent an evolving area of research regarding how genetic testing might one day influence monitoring plans. Talk to your dermatologist or oncologist about whether your specific pathology report includes genetic screening relevant to your risk.
The takeaway
Genetic signatures may eventually provide a more precise way to gauge the risk of melanoma returning than stage alone. Keep track of your pathology results and discuss any questions about personalized risk assessment during your routine follow-up appointments.
Further reading
You can find more information on emerging prognostic tools in our Cancer section.
More information
View the complete biorxiv research article for technical details on the study design.
Source note: This article includes information reported by Biorxiv.
Live Poll
Do you believe new genetic research methods will significantly improve future cancer treatment outcomes?
